[1]任邦嘉欣 陈明.高血压前期的研究进展[J].心血管病学进展,2021,(4):356-359.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.016]
　REN Bangjiaxin,CHEN Ming.Research Progress in Pre-hypertension[J].Advances in Cardiovascular Diseases,2021,(4):356-359.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.016]

点击复制

高血压前期的研究进展()

分享到：

参考文献/References:

[ 1]Chobanian AV,Bakris GL,Black HR,et al. The Seventh Report of the Joint National Committee on Prevention,Detection,Evaluation,and Treatment of High Blood Pressure :the JNC 7 report [J]. JAMA,2003,289(19):2560-2572.

[2] 中国高血压防治指南修订委员会,高血压联盟(中国) , 中华医学会心血管病学分会 , 等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志,2019,24(1):24-56.

[3]Whelton PK,Carey RM,Aronow WS,et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention,Detection,Evaluation,and Management of High Blood Pressure in Adults:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [J]. Hypertension,2018,71(6):e13-e115.

[4 ] Xu T , Liu J , Zhu G , et al. Prevalence of prehypertension and associated risk factors among Chinese adults from a large-scale multi-ethnic population survey[J]. BMC Public Health , 2016 , 16(1): 775 .

[5]Kim Y, Lee S. P revalence and risk factors associated with prehypertension by gender and age in a Korean population in the KNHANES 2010 - 2012[J]. Iran J Public Health , 2015 , 44(12):1594-1602.

[6 ] Tabrizi JS , Sadeghi-Bazargani H , Farahbakhsh M , et al. Prevalence and associated factors of prehypertension and hypertension in Iranian population : the Lifestyle Promotion Project (LPP ) [J]. Plos One , 2016 , 11(10): e0165264.

[7 ] Booth JN , Li J , Zhang L , et al. Trends in prehypertension and hypertension risk factors in US adults : 1999-2012 [ J]. Hypertension , 2017 , 70(2):275-284.

[8 ] Raphadu TT , Staden MV , Dibakwane WM , et al. A Non-Invasive Investigation into the Prevalence of Higher than Normal Blood Pressure , Hypertension and the Association between Blood Pressure and Body Weight in Male and Female Adolescents in the Polokwane Local Municipality , Limpopo-South Africa : A Cross-Sectional Study[J]. Children(Basel) , 2020 , 7(3) : 18 .

[9 ] Kringeland E , Tell GS , Midt b?H , et al. Factors associated with increase in blood pressure and incident hypertension in early midlife : the Hordaland Health Study[J]. Blood Press , 2020 , 29(5) : 267-275 .

[10 ] Jiang M , Gong D , Fan Y. Serum uric acid levels and risk of prehypertension : a meta-analysis[J]. Clin Chem Lab Med , 2017 , 55(3):314-321.

[11 ] Talikoti P , Bobby Z , Hamide A. Hyperhomocysteinemia , insulin resistance and high HS - CRP levels in prehypertension[J]. J Clin Diagn Res , 2014 , 8(8):CC07- CC 0 9.

[12 ] Wrobel TP , Piergies N , Pieta E , et al. Erythrocyte hem e- oxygenation status indicated as a risk factor in prehypertension by Raman spectroscopy[J]. Biochim Biophys Acta Mol Basis Dis , 2018 , 1864(11):3659-3663.

[13 ] Whelton SP, McEvoy JW , Shaw L , et al. Association of normal systolic blood pressure level with cardiovascular disease in the absence of risk factors [ J]. JAMA Cardiol , 2020 , 5(9):1011-1018.

[14 ] Chen X , Barywani SB , Hansson PO , et al. High-normal blood pressure conferred higher risk of cardiovascular disease in a random population sample of 50-year-old men : A 21-year follow-up[J]. Medicine (Baltimore) , 2020 , 99(17):e19895.

[15 ] National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ). Third Report of th e National Cholesterol Education Program (NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults(Adult Treatment Panel Ⅲ)final report[J]. Circulation,2002,106(25):3143-3421.

[16]Kachur S,Morera R,De Schutter A,et al. Cardiovascular Risk in Patients with Prehypertension and the Metabolic Syndrome[J]. Curr Hypertens Rep ,2018,20(2):15.

[17 ] Mullican DR , Lorenzo C , Haffner SM. Is prehypertension a risk factor for the development of type 2 diabetes ? [J]. Diabetes Care , 2009 , 32(10):1870-1872.

[18 ] Jung JY , Park SK , Oh CM , et al. The influence of prehypertension , controlled and uncontrolled hypertension on left ventricular diastolic function and structure in the general Korean population[J]. Hypertens Res , 2017 , 40(6):606-612.

[19 ] Li Y , Xia P , Xu L ,e t al. A meta-analysis on prehypertension and chronic kidney disease[J]. Plos One , 2016 , 11(6):e0156575.

[20]Wang Q,Huang J,Sun Y,et al. Association of microalbuminuria with diabetes is stronger in people with prehypertension compared to those with ideal blood pressure[J]. Nephrology (Carlton),2018,23(7):690-696.

[21]Turgunova L,Koichubekov B,Turmuhambetova A,et al. Biochemical markers of hypertension,prehypertension[J]. Ann Cardiol Angeiol (Paris) ,2018,67(3):161-166.

[22 ] Zaiou M. Circular RNAs in hypertension : challenges and clinical promise[J]. Hypertens Res , 2019 , 42(11):1653-1663.

[23 ] Wu N , Jin L , Cai J. Profiling and bioinformatics analyses reveal differential circular RNA expression in hypertensive patients[J]. Clin Exp Hypertens , 2017 , 39(5):454-459.

[24 ] Saneei P , Salehi-Abargouei A , Esmaillzadeh A , et al. Influence of Dietary Approaches to Stop Hypertension(DASH ) diet on blood pressure : a systematic review and meta-analysis on randomized controlled trials[J]. Nutr Metab Cardiovasc Dis , 2014 , 24(12):1253-1261.

[25 ] Hashemi R , Rahimlou M , Baghdadian S , et al. Investigating the effect of DASH diet on blood pressure of patients with type 2 diabetes and prehypertension : randomized clinical trial[J]. Diabetes Metab Syndr , 2019 , 13(1):1-4.

[26 ] Volpe M , Gallo G , Tocci G. Novel blood pressure targets in patients with high-normal levels and grade 1 hypertension : room for monotherapy ? [J]. Int J Cardiol , 2019 , 291:105- 1 11.

[27 ] Fuchs SC , Poli - de - Figueiredo CE,Figueiredo Neto JA,et al. Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension:The PREVER-Prevention Randomized Clinical Trial[J]. J Am Heart Assoc,2016,5(12):e004248.

[28 ] Thomopoulos C , Parati G , Zanchetti A . Effects of blood-pressure-lowering treatment on outcome incidence . 12 . Effects in individuals with high-normal and normal blood pressure : overview and meta-analyses of randomized trials[J]. J Hypertens , 2017 , 35(11):2150-2160.

[29 ] Kario K , Okada K , Kato M , et al. 24-Hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension:results from the randomized , placebo-controlled SACRA study[J]. Circulation , 2018 , 139(18):2089-2097.

[30 ] Ferdinand KC , Balavoine F , Besse B , et al. Efficacy and safety of firibastat , a first-in-class brain aminopeptidase a inhibitor , in hypertensive overweight patients of multiple ethnic origins[J]. Circulation , 2019 , 140(2):138-146.

[31 ] Giles TD , Materson BJ , Cohn JN , et al. Definition and classification of hypertension:an update[J]. J Clin Hypertens (Greenwich),2009,11(11):611-614.

相似文献/References:

[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
　BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(4):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
　REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(4):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
　YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(4):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
　ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(4):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
　QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(4):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
　JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(4):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
　HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(4):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
　Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(4):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
　WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(4):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]